Benign prostatic hyperplasia (BPH) and lower urinary tract symptoms are bothersome and costly conditions affecting nearly half of men older than age 50 years and 90% of men older than age 80. In the search for more effective noninvasive therapies, the role of the neural activity in BPH has been studied. Botulinum toxin injection has been used for several urological conditions including voiding dysfunction, and studies have shown that intraprostatic injection may be beneficial in lower urinary tract symptoms secondary to BPH.
Eligible men were randomized in a 1:1 ratio to a 100 or a 300 U dose of onabotulinum toxin A. The study was double-blind as to the toxin dose. The drug was injected transrectally into the prostatic peripheral transitional zone with ultrasound guidance. It was administered as 2 cc per lobe in 1 ml aliquots at 2 injection sites for a total of 4 sites.
Men were contacted by telephone at 1 week after treatment, and evaluated in person at 1, 2, 3, 6, 9 and 12 months. Uroflowmetry, vital signs, AUASI and medical conditions were collected or performed at baseline and each visit; transrectal ultrasound and questionnaires on the impact of BPH, bladder function, erectile function and ejaculatory function were administered at baseline, and 3 and 12 months; bladder ultrasound was performed at baseline and 12 months; and physical and digital rectal examination, and prostate specific antigen were determined at baseline, and at 3, 6 and 12 months.
To determine whether two different doses (100 U and 300 U) of onabotulinum toxin A injection into the prostate gland demonstrate sufficient improvement in the management of lower urinary symptoms due to BPH to warrant more extensive research.
The primary outcome was treatment success at 3 months post-treatment, defined as:
Improvement in the American Urological Association symptom index (AUASI) by at least 30% and/or
Urinary flow rate (Qmax) improvement of more than 30%, each determined from baseline to 3 months after injection.
In addition, two safety criteria also had to be met. A dose failed if either:
Any reported event was determined to be related to the onabotulinum toxin A injection and was considered life threatening, disabling, or fatal
≥ 40% of the participants reported a moderate or severe side effect related to the botulinum toxin injection.
A total of 134 men were randomized and treated (68 with 100 units, 66 with 300 units), with 131 assessed at 3 months and 108 assessed at 12 months. Each dose met the 3-month primary outcome criteria. In the 100 unit arm the mean baseline AUASI score of 18.8 decreased by 7.1 and 6.9 at 3 and 12 months, respectively. In the 300 unit arm the baseline of 19.5 decreased by 8.9 and 7.1, respectively. In the 100 unit arm the mean baseline maximum urinary flow rate of 10.0 ml per second increased by 2.5 and 2.2, respectively, and in the 300 unit arm the baseline of 9.6 increased by 2.6 and 2.3, respectively. (J Urol. 2011 Sep;186(3):965-70.)
Urologic Diseases
Interventional
7
2006-10
2009-12
Benign Prostatic Hyperplasia
Urinary Flow Rate (Qmax), Digital Rectal Examination, Benign Prostatic Hyperplasia (BPH), Botulinum toxin, Onabotulinum Toxin A, Bladder, American Urological Association Symptom Index (AUASI)
Division of Kidney, Urologic, and Hematologic Diseases
Document Name | Description | Document Type | File Format | Compliance | Download |
---|---|---|---|---|---|
Dataset Name | Description | # of Records | # of Variables | File Format(s) |
---|---|---|---|---|
Form SCR1 - Screening Visit 2 Dataset | Contains data from Form SCR1 - Screening Visit 2 | 134 | sas7bdat (33 KB); csv (9.39 KB) | |
Form BLAD - Bladder Function Dataset | Contains data from Form BLAD - Bladder Function | 381 | sas7bdat (33 KB); csv (9.39 KB) | |
Form M06 - Visit for Month 6 Dataset | Contains data from Form M06 - Visit for Month 6 | 126 | sas7bdat (49 KB); csv (13.07 KB) | |
Form W12M12 - Visits for Week 12 and Month 12 Dataset | Contains data from Form W12M12 - Visits for Week 12 and Month 12 | 253 | sas7bdat (113 KB); csv (33.7 KB) | |
Form EREC - Erectile Function Dataset | Contains data from Form EREC - Erectile Function | 382 | sas7bdat (41 KB); csv (10.94 KB) | |
Form EJAC - Ejaculatory Function Dataset | Contains data from Form EJAC - Ejaculatory Function | 381 | sas7bdat (33 KB); csv (8.66 KB) | |
Form AUA - AUA Symptoms Score Dataset | Contains data from Form AUA - AUA Symptoms Score | 1010 | sas7bdat (81 KB); csv (24.76 KB) | |
Form W4W8M9 - Visits at Week 4, Week 8, or Month 12 Dataset | Contains data from Form W4W8M9 - Visits at Week 4, Week 8, or Month 12 | 389 | sas7bdat (81 KB); csv (26.33 KB) | |
Form TX0 - Botulinum Toxin Injection Dataset | Contains data from Form TX0 - Botulinum Toxin Injection | 134 | sas7bdat (81 KB); csv (28.21 KB) | |
Form IMPA - BPH Impact Scale Dataset | Contains data from Form IMPA - BPH Impact Scale | 383 | sas7bdat (21 KB); csv (7.17 KB) | |
Form SCR1 - Screening Visit 1 Dataset | Contains data from Form SCR1 - Screening Visit 1 | 134 | sas7bdat (113 KB); csv (32.8 KB) |